Mira Pharmaceuticals develops topical Ketamir-2 for localized pain; preclinical study underway

MIRA PHARMACEUTICALS, INC.

Topical Ketamir-2 designed for slow release, enabling targeted pain relief with minimal systemic exposure.
Preclinical study assessing efficacy of topical formulation against inflammatory pain is ongoing.
Phase 1 oral trial for Ketamir-2 continues; Phase 2a in diabetic neuropathy planned by year-end 2025.
First human efficacy data from Phase 2a expected in Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.